Silke Gillessen, in conversation with Alicia Morgans provides an overview of many of the changes taking place in prostate cancer clinical practice since the 2017 APCCC. They touch upon the new data that is driving change in clinical practice and some unanswered questions that have arisen and will be discussed in the upcoming 2019 Advanced Prostate Cancer Consensus Conference (APCCC 2019).  The next APCCC is scheduled for August 29 - 31, 2019 in Basel, Switzerland. These topics include the many new trials, the approval of apalutamide and anticipated approvals of other drugs in M0 CRPC, as well as data and approvals of novel imaging agents.  The APCCC provides an update on the current standard of advanced prostate cancer management and a global discussion amongst attendees on questions that occur in daily clinical practice for which there is limited evidence-based data.  

Biographies:  
Silke Gillessen, MD, Professor Medical Oncology, University of Berne, Switzerland. Co-founder of the Advanced Prostate Cancer Consensus Conference (APCCC).  Silke Gillessen has an excellent reputation in the field of urogenital tumors and due to her specialist knowledge, she is a member of numerous oncology and expert boards. She has numerous research publications and since 1995, she is engaged in collaboration and leadership (as sub-investigator or principal investigator) in multiple clinical trials (Phase I-III) including first-in-man trials.  Silke Gillessen graduated from the Medical School of the University in Basel, Switzerland. 

Alicia Morgans, MD, MPH

Read More:

Silke Gillessen's EAU 2018 Presentation: Systemic Therapy is the Standard of Care

APCCC 2017 Full Coverage